The company merged with Jianru Pharmaceutical Co., Ltd. by the resolution of the board of directors on May 8, 107, and held a press conference at 17:30 p.m. on May 8, 107 at the securities trading center, and the press release reads as follows:
Uni Pharma Co., Ltd. (hereinafter referred to as Huayu Pharmaceutical, code: 6621) and Jianru Pharmaceutical Co., Ltd. (hereinafter referred to as Jianru) are integrating resources, enhancing the company’s competitiveness, and promoting the company’s new drug research and development energy. The two companies held a meeting of the board of directors today (08/05/107) to approve the merger.
Under this structure, Huayu Pharmaceutical is the surviving company, and Jianru is the elimination company; The name of the surviving company after the merger is “Uni Pharma Co., Ltd..” The tentative share exchange ratio between Jianru and Huayu Pharmaceutical is 1:1 (i.e., 1 ordinary share of Huayu Pharmaceutical will be exchanged for every 1 ordinary share of Jianru), and the paid-in capital of Huayu Pharmaceutical after the merger will be approximately 354 million yuan. The proposal will be discussed and approved at the general meeting of shareholders of the two companies on June 19, 107 and approved by the competent authority, and the merger base date is tentatively set at September 1, 107.
(1) The core of Huayu Pharmaceutical’s operation is mainly the agency marketing of medical services and products close to the clinical end, and the outstanding results of ADEPT anti-stick solution in the marketing of Huayu Pharmaceutical are confirmed by the original Baxter Healthcare. ADEPT Anti-Sticking Solution provides all-round protection and reduces the effect of sticking during abdominal surgery, and is widely trusted and widely used by clinicians.
(2) Huayu Pharmaceutical deeply understands the advantages and future development of minimally invasive surgery in the diagnosis and treatment of cancer with tumor marker DR-70 enzyme immunoassay diagnostic reagent (DR-70) and radiofrequency ablation technology (RFA), so it cooperates with ITRI to develop RFA’s minimally invasive liver cancer related needles and cooperates with the guidance system of Haoyu Biomedical Co., Ltd. to develop RFA 2.0 into the world in the future.
(3) Jianru is a specialty drug R&D company specializing in the development of innovative dosage forms, searching for new products (505 B2 new drugs) with patient needs and market competitiveness, including high-tech or patent-related barriers, high-entry barriers to scientific generic drugs, and patented oral solid release control agent technology platform applications.
(4) Through the R&D expertise of Jianru, Huayu Pharmaceutical has transformed from an agent marketing professional to an internationally competitive R&D pharmaceutical company.
(5) Huayu Pharmaceutical and Jianru are the upstream and downstream relationship of the biotechnology and pharmaceutical industry, so if the two parties merge, Huayu Pharmaceutical’s marketing expertise and Jianru’s R&D energy will complement each other, which can not only promote the existing cooperative projects more effectively, but also quickly find the most internationally competitive products under the “one-stop” operation, establish an innovative and marketable product pipeline, and enhance the company’s value.
